Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT ID: NCT02625480
Last Updated: 2025-09-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
95 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-02-01
Study Completion Date
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).
As of October 2022, no further patients with acute B-cell Acute Lymphoblastic Leukemia (ALL) will be asked to join the study. The study remains open for recruitment for patients that have B-cell Non Hodgkin Lymphoma (NHL).
As of October 2022, no further patients with acute B-cell Acute Lymphoblastic Leukemia (ALL) will be asked to join the study. The study remains open for recruitment for patients that have B-cell Non Hodgkin Lymphoma (NHL).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
NCT02614066
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
COMPLETED
PHASE1/PHASE2
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT03624036
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
TERMINATED
PHASE1
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT06253663
Relapsed/Refractory Mantle Cell Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
ACTIVE_NOT_RECRUITING
PHASE2
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
NCT05537766
Relapsed/Refractory Waldenstrom Macroglobulinemia
Relapsed/Refractory Richter Transformation
Relapsed/Refractory Burkitt Lymphoma
+1 more
TERMINATED
PHASE2
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
NCT05460533
B-cell Acute Lymphoblastic Leukemia
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All participants who received KTE-X19, and have completed at least 24 months of protocol assessments, will be transitioned to a separate long-term follow-up (LTFU) study. The purpose of the LTFU study (KT-US-982-5968.) is to complete the remainder of the 15-year follow-up assessments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR+ T cells/kg or 1 x 10\^6 anti-CD19 CAR+ T cells/kg.
Group Type
EXPERIMENTAL
Brexucabtagene Autoleucel (KTE-X19)
Intervention Type
BIOLOGICAL
Fludarabine
Intervention Type
DRUG
Administered intravenously
Cyclophosphamide
Intervention Type
DRUG
Administered intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brexucabtagene Autoleucel (KTE-X19)
Intervention Type
BIOLOGICAL
Fludarabine
Administered intravenously
Intervention Type
DRUG
Cyclophosphamide
Administered intravenously
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed or refractory B-precursor ALL defined as one of the following:
* Primary refractory disease
* Any relapse within 18 months after first diagnosis
* Relapsed or refractory disease after 2 or more lines of systemic therapy
* Relapsed or refractory disease after allogeneic transplant provided individual is at least 100 days from stem cell transplant at the time of enrollment
* Disease burden defined as at least 1 of the following:
* Morphological disease in the bone marrow (\> 5% blasts)
* Minimal/Measurable Residual Disease (MRD) positive (threshold 10\^-4 by flow or Polymerase chain reaction (PCR))
* Individuals with Ph+ disease are eligible if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite treatment with at least 2 different TKIs
* Age ≤ 21 years and weight ≥ 6 kg at the time of assent or consent per Institutional Review Board (IRB) guidelines
* Lansky (age \< 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at the time of assent/consent) performance status ≥ 80 at screening
* Adequate renal, hepatic, pulmonary and cardiac function defined as:
* Creatinine clearance (as estimated by Cockcroft Gault or Schwartz) ≥ 60 mL/min
* Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 x ULN, except in individuals with Gilbert's syndrome
* Left ventricular shortening fraction (LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%, as determined by an echocardiogram or multi-gated acquisition scan (MUGA), no evidence of pericardial effusion (except trace or physiological) as determined by an echocardiogram (ECHO) and no clinically significant arrhythmias
* No clinically significant pleural effusion, pericardial effusion or ascites
* Baseline oxygen saturation \> 92% on room air
* Histologically confirmed aggressive B cell NHL
* Relapsed or refractory histologically confirmed aggressive B-cell NHL per 1 or more of the following:
* Primary refractory disease
* Any relapse within 18 months after first diagnosis
* Relapsed or refractory disease after 1 or more lines of systemic therapy
* Relapsed or refractory disease after autologous /allogeneic stem cell transplant provided individual is at least 6 weeks from autologous stem cell transplant and at least 3 months from allogeneic stem cell transplant at the time of enrollment
* Individuals must have received adequate prior therapy including at a minimum all of the following:
* Anti-CD20 monoclonal antibody, unless the investigator determines that the tumor is CD20 negative
* An anthracycline-containing chemotherapy regimen
* Age \<18 years old and weight ≥ 6kg
* Lansky (age \< 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at the time of assent/consent) performance status ≥ 80 at screening
* Adequate renal, hepatic, pulmonary, and cardiac function defined as the following:
* Creatinine clearance (as estimated by Cockcroft Gault or Schwartz) ≥ 60 mL/min
* Serum ALT/AST ≤ 5 ULN
* Total bilirubin ≤1.5 x ULN except in individuals with Gilbert's syndrome
* Left ventricular shortening fraction(LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%, as determined by ECHO or MUGA, no evidence of pericardial effusion (except trace or physiological) as determined by an ECHO, and no clinically significant arrhythmias
* Baseline oxygen saturation \> 92% on room air
* Primary refractory disease
* Any relapse within 18 months after first diagnosis
* Relapsed or refractory disease after 2 or more lines of systemic therapy
* Relapsed or refractory disease after allogeneic transplant provided individual is at least 100 days from stem cell transplant at the time of enrollment
* Disease burden defined as at least 1 of the following:
* Morphological disease in the bone marrow (\> 5% blasts)
* Minimal/Measurable Residual Disease (MRD) positive (threshold 10\^-4 by flow or Polymerase chain reaction (PCR))
* Individuals with Ph+ disease are eligible if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite treatment with at least 2 different TKIs
* Age ≤ 21 years and weight ≥ 6 kg at the time of assent or consent per Institutional Review Board (IRB) guidelines
* Lansky (age \< 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at the time of assent/consent) performance status ≥ 80 at screening
* Adequate renal, hepatic, pulmonary and cardiac function defined as:
* Creatinine clearance (as estimated by Cockcroft Gault or Schwartz) ≥ 60 mL/min
* Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 x ULN, except in individuals with Gilbert's syndrome
* Left ventricular shortening fraction (LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%, as determined by an echocardiogram or multi-gated acquisition scan (MUGA), no evidence of pericardial effusion (except trace or physiological) as determined by an echocardiogram (ECHO) and no clinically significant arrhythmias
* No clinically significant pleural effusion, pericardial effusion or ascites
* Baseline oxygen saturation \> 92% on room air
* Histologically confirmed aggressive B cell NHL
* Relapsed or refractory histologically confirmed aggressive B-cell NHL per 1 or more of the following:
* Primary refractory disease
* Any relapse within 18 months after first diagnosis
* Relapsed or refractory disease after 1 or more lines of systemic therapy
* Relapsed or refractory disease after autologous /allogeneic stem cell transplant provided individual is at least 6 weeks from autologous stem cell transplant and at least 3 months from allogeneic stem cell transplant at the time of enrollment
* Individuals must have received adequate prior therapy including at a minimum all of the following:
* Anti-CD20 monoclonal antibody, unless the investigator determines that the tumor is CD20 negative
* An anthracycline-containing chemotherapy regimen
* Age \<18 years old and weight ≥ 6kg
* Lansky (age \< 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at the time of assent/consent) performance status ≥ 80 at screening
* Adequate renal, hepatic, pulmonary, and cardiac function defined as the following:
* Creatinine clearance (as estimated by Cockcroft Gault or Schwartz) ≥ 60 mL/min
* Serum ALT/AST ≤ 5 ULN
* Total bilirubin ≤1.5 x ULN except in individuals with Gilbert's syndrome
* Left ventricular shortening fraction(LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%, as determined by ECHO or MUGA, no evidence of pericardial effusion (except trace or physiological) as determined by an ECHO, and no clinically significant arrhythmias
* Baseline oxygen saturation \> 92% on room air
Exclusion Criteria
* Diagnosis of Burkitt's leukemia/lymphoma according to the World Health Organization (WHO) classification or chronic myelogenous leukemia lymphoid blast crisis
* History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years
* History of severe hypersensitivity reaction to aminoglycosides or any of the agents used in this study
* Central nervous system (CNS) involvement and abnormalities:
* Any CNS tumor mass by imaging and/or parameningeal mass (cranial and/or spinal)
* Presence of central nervous system (CNS)-3 disease, defined as white blood cell (WBC) ≥ 5/µL in Cerebrospinal Fluid (CSF) with presence of lymphoblasts with or without neurologic symptoms
* CNS-2 disease, defined as WBC \< 5/µL in CSF with presence of lymphoblasts and with neurologic symptoms (see note below for further clarification).
* Note: Neurologic symptoms may include but are not limited to cranial nerve palsy (if not explained by extracranial tumor) and clinical cord compression.
* (Individuals with CNS-1 (no detectable lymphoblasts in the CSF) and those with CNS-2 without clinically evident neurological changes are eligible to participate in the study)
* History or presence of CNS disorder, such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema with confirmed structural defects not related to lymphoma by appropriate imaging. History of stroke or transient ischemic attack within 12 months before enrollment. Individuals with seizure disorders requiring active anticonvulsive medication.
* History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
* Primary immunodeficiency
* History of human immunodeficiency virus (HIV) infection or acute / chronic active hepatitis B or C infection. Individuals with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines.
* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
* Prior medication:
* Prior CD19 directed therapy (other than blinatumomab), including CAR+ T cell, bispecific T cell engager (BiTE), and antibody drug conjugate (ADC), with the exception of individuals who received brexucabtagene autoleucel (KTE-X19) in this study and are eligible for re-treatment
* Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis
* Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
* Any drug used for graft-versus-host disease (GVHD) within 4 weeks prior to enrollment
* Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment
* Live vaccine ≤ 6 weeks prior to enrollment
* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization are not considered to be of childbearing potential
* Individuals of both genders of child-bearing potential who are not willing to use a birth control method considered to be highly effective per protocol from the time of consent through 6 months after conditioning chemotherapy or brexucabtagene autoleucel (KTE-X19) infusion, whichever is longer.
* History of malignancy other than nonmelanoma skin cancer, carcinoma in situ (eg, cervix, breast), or follicular lymphoma (FL) unless disease free for at least 3 years
* Autologous stem cell transplant within \<6 weeks of planned KTE-X19 infusion; allogeneic stem cell transplant within \<3 months of planned KTE-X19 infusion
* Prior CD19 targeted therapy other than blinatumomab and loncastuximab tesirine-lpyl
* History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
* History of HIV infection or acute/chronic active hepatitis B or C infection. Individuals with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines
* Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by International Bone Marrow Transplant Registry (IBMTR) index; acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment.
* CNS involvement and abnormalities:
* Any CNS tumor mass and/or parameningeal mass (cranial and/or spinal) by imaging with current or prior history of neurological symptoms within 3 months prior to screening.
Note: CNS involvement without neurologic symptoms will be allowed.
* History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema with confirmed structural defects by appropriate imaging. History of stroke or transient ischemic attack within 12 months before enrollment. Individuals with seizure disorders requiring active anti-convulsive medication.
* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
* Primary immunodeficiency
* History of severe immediate hypersensitivity reaction to any of the agents used in this study
* Live vaccine ≤ 6 weeks prior to planned start of lymphodepleting chemotherapy regimen
* Individuals of both genders of child-bearing potential who are not willing to use a birth control considered to be highly effective per protocol from the time of consent through 12 months after the completion of lymphodepleting chemotherapy or brexucabtagene autoleucel (KTE-X19) infusion, whichever is longer.
* Prior medication:
* Prior CD19 directed therapy (other than blinatumomab), including CAR+ T cell, BiTE, and ADC, with the exception of individuals who received brexucabtagene autoleucel (KTE-X19) in this study and are eligible for re-treatment
* Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis
* DLI within 28 days prior to enrollment
* Any drug used for GVHD within 4 weeks prior to enrollment
* History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years
* History of severe hypersensitivity reaction to aminoglycosides or any of the agents used in this study
* Central nervous system (CNS) involvement and abnormalities:
* Any CNS tumor mass by imaging and/or parameningeal mass (cranial and/or spinal)
* Presence of central nervous system (CNS)-3 disease, defined as white blood cell (WBC) ≥ 5/µL in Cerebrospinal Fluid (CSF) with presence of lymphoblasts with or without neurologic symptoms
* CNS-2 disease, defined as WBC \< 5/µL in CSF with presence of lymphoblasts and with neurologic symptoms (see note below for further clarification).
* Note: Neurologic symptoms may include but are not limited to cranial nerve palsy (if not explained by extracranial tumor) and clinical cord compression.
* (Individuals with CNS-1 (no detectable lymphoblasts in the CSF) and those with CNS-2 without clinically evident neurological changes are eligible to participate in the study)
* History or presence of CNS disorder, such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema with confirmed structural defects not related to lymphoma by appropriate imaging. History of stroke or transient ischemic attack within 12 months before enrollment. Individuals with seizure disorders requiring active anticonvulsive medication.
* History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
* Primary immunodeficiency
* History of human immunodeficiency virus (HIV) infection or acute / chronic active hepatitis B or C infection. Individuals with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines.
* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
* Prior medication:
* Prior CD19 directed therapy (other than blinatumomab), including CAR+ T cell, bispecific T cell engager (BiTE), and antibody drug conjugate (ADC), with the exception of individuals who received brexucabtagene autoleucel (KTE-X19) in this study and are eligible for re-treatment
* Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis
* Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
* Any drug used for graft-versus-host disease (GVHD) within 4 weeks prior to enrollment
* Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment
* Live vaccine ≤ 6 weeks prior to enrollment
* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization are not considered to be of childbearing potential
* Individuals of both genders of child-bearing potential who are not willing to use a birth control method considered to be highly effective per protocol from the time of consent through 6 months after conditioning chemotherapy or brexucabtagene autoleucel (KTE-X19) infusion, whichever is longer.
* History of malignancy other than nonmelanoma skin cancer, carcinoma in situ (eg, cervix, breast), or follicular lymphoma (FL) unless disease free for at least 3 years
* Autologous stem cell transplant within \<6 weeks of planned KTE-X19 infusion; allogeneic stem cell transplant within \<3 months of planned KTE-X19 infusion
* Prior CD19 targeted therapy other than blinatumomab and loncastuximab tesirine-lpyl
* History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
* History of HIV infection or acute/chronic active hepatitis B or C infection. Individuals with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines
* Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by International Bone Marrow Transplant Registry (IBMTR) index; acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment.
* CNS involvement and abnormalities:
* Any CNS tumor mass and/or parameningeal mass (cranial and/or spinal) by imaging with current or prior history of neurological symptoms within 3 months prior to screening.
Note: CNS involvement without neurologic symptoms will be allowed.
* History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema with confirmed structural defects by appropriate imaging. History of stroke or transient ischemic attack within 12 months before enrollment. Individuals with seizure disorders requiring active anti-convulsive medication.
* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
* Primary immunodeficiency
* History of severe immediate hypersensitivity reaction to any of the agents used in this study
* Live vaccine ≤ 6 weeks prior to planned start of lymphodepleting chemotherapy regimen
* Individuals of both genders of child-bearing potential who are not willing to use a birth control considered to be highly effective per protocol from the time of consent through 12 months after the completion of lymphodepleting chemotherapy or brexucabtagene autoleucel (KTE-X19) infusion, whichever is longer.
* Prior medication:
* Prior CD19 directed therapy (other than blinatumomab), including CAR+ T cell, BiTE, and ADC, with the exception of individuals who received brexucabtagene autoleucel (KTE-X19) in this study and are eligible for re-treatment
* Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis
* DLI within 28 days prior to enrollment
* Any drug used for GVHD within 4 weeks prior to enrollment
Maximum Eligible Age
21 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kite, A Gilead Company
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kite Study Director
Role: STUDY_DIRECTOR
Kite, A Gilead Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital Los Angeles
Los Angeles, California, United States
Site Status
Children's Hospital of Orange County
Orange, California, United States
Site Status
UCSF Benioff Children's Hospital
San Francisco, California, United States
Site Status
University of Miami Hospital & Clinics
Miami, Florida, United States
Site Status
Kapi'olani Medical Center for Women and Children
Honolulu, Hawaii, United States
Site Status
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois, United States
Site Status
Johns Hopkins University
Baltimore, Maryland, United States
Site Status
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, United States
Site Status
Columbia University Irving Medical Center/Morgan Stanley Children's Hospital-NYP
New York, New York, United States
Site Status
University of Rochester Medical Center
Rochester, New York, United States
Site Status
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site Status
Monroe-Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, United States
Site Status
Texas Children's Hospital
Houston, Texas, United States
Site Status
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Site Status
University of Virginia Health System, Pediatric Hematology/Oncology Clinic
Charlottesville, Virginia, United States
Site Status
University Hospital Gent
Ghent, , Belgium
Site Status
The Hospital for Sick Children
Toronto, , Canada
Site Status
University Hospital Brno
Brno, , Czechia
Site Status
Unité d'Oncologie et Hématologie Pédiatriques
Bordeaux, , France
Site Status
Institut d'Hematologie et Oncologie Pediatrique
Lyon, , France
Site Status
Hopital d'Enfants la Timone
Marseille, , France
Site Status
Hopital Robert Debre - Sevice d'Hemato-immunologic
Paris, , France
Site Status
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, , Germany
Site Status
Bambino Gesù Children's Hospital
Rome, , Italy
Site Status
Prinses Maxima Centrum
Utrecht, , Netherlands
Site Status
Jurasz University Hospital 1; Collegium Medicum
Bydgoszcz, , Poland
Site Status
Wroclaw Medical University
Wroclaw, , Poland
Site Status
Hospital Sant Joan de Déu
Barcelona, , Spain
Site Status
Hospital Universitario La Paz
Madrid, , Spain
Site Status
Karolinska University Hospital
Stockholm, , Sweden
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Belgium
Canada
Czechia
France
Germany
Italy
Netherlands
Poland
Spain
Sweden
References
Explore related publications, articles, or registry entries linked to this study.
Wayne AS, Huynh V, Hijiya N, Rouce RH, Brown PA, Krueger J, Kitko CL, Ziga ED, Hermiston ML, Richards MK, Baruchel A, Schuberth PC, Rossi J, Zhou L, Goyal L, Jain R, Vezan R, Masouleh BK, Lee DW. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 Mar 1;108(3):747-760. doi: 10.3324/haematol.2022.280678.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.gileadclinicaltrials.com/study/?id=KTE-C19-104
Gilead Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509440-97
Identifier Type: OTHER
Identifier Source: secondary_id
KTE-C19-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
NCT05775406
COMPLETED
PHASE1
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
NCT02808442
COMPLETED
PHASE1
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
NCT02228096
COMPLETED
PHASE2
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
NCT02370160
COMPLETED
PHASE1/PHASE2
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
NCT06287229
RECRUITING
PHASE1/PHASE2
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects
NCT03265106
UNKNOWN
PHASE1/PHASE2
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
NCT02187354
NO_LONGER_AVAILABLE
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT01471782
COMPLETED
PHASE1/PHASE2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
NCT02435849
COMPLETED
PHASE2
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT01363817
COMPLETED
PHASE1
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects
NCT03156101
UNKNOWN
PHASE1/PHASE2
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
NCT06607419
RECRUITING
PHASE2/PHASE3
Blinatumomab Bridging Therapy for BALL
NCT04556084
TERMINATED
PHASE2
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
NCT05667506
RECRUITING
PHASE1/PHASE2
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
NCT03825367
UNKNOWN
PHASE1/PHASE2
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT05310591
RECRUITING
PHASE1/PHASE2
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
NCT03605589
WITHDRAWN
PHASE1
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
NCT03114865
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Phase III B in Acute Lymphoblastic Leukemia
NCT03123939
COMPLETED
PHASE3
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
NCT00087204
COMPLETED
PHASE1
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
NCT02167360
WITHDRAWN
PHASE2
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02013167
TERMINATED
PHASE3
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01466179
COMPLETED
PHASE2
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960
RECRUITING
PHASE2